Co-Authors
This is a "connection" page, showing publications co-authored by Thanigaivelan Kanagasabai and Samuel Adunyah.
Connection Strength
0.371
-
Kanagasabai T, Li G, Shen TH, Gladoun N, Castillo-Martin M, Celada SI, Xie Y, Brown LK, Mark ZA, Ochieng J, Ballard BR, Cordon-Cardo C, Adunyah SE, Jin R, Matusik RJ, Chen Z. MicroRNA-21 deficiency suppresses prostate cancer progression through downregulation of the IRS1-SREBP-1 signaling pathway. Cancer Lett. 2022 01 28; 525:46-54.
Score: 0.204
-
Brown LK, Kanagasabai T, Li G, Celada SI, Rumph JT, Adunyah SE, Stewart LV, Chen Z. Co-targeting SKP2 and KDM5B inhibits prostate cancer progression by abrogating AKT signaling with induction of senescence and apoptosis. Prostate. 2024 Jun; 84(9):877-887.
Score: 0.061
-
Celada SI, Li G, Celada LJ, Lu W, Kanagasabai T, Feng W, Cao Z, Salsabeel N, Mao N, Brown LK, Mark ZA, Izban MG, Ballard BR, Zhou X, Adunyah SE, Matusik RJ, Wang X, Chen Z. Lysosome-dependent FOXA1 ubiquitination contributes to luminal lineage of advanced prostate cancer. Mol Oncol. 2023 10; 17(10):2126-2146.
Score: 0.058
-
Li G, Kanagasabai T, Lu W, Zou MR, Zhang SM, Celada SI, Izban MG, Liu Q, Lu T, Ballard BR, Zhou X, Adunyah SE, Matusik RJ, Yan Q, Chen Z. KDM5B Is Essential for the Hyperactivation of PI3K/AKT Signaling in Prostate Tumorigenesis. Cancer Res. 2020 11 01; 80(21):4633-4643.
Score: 0.047